HighTower Advisors LLC Cuts Position in Dynavax Technologies Co. (NASDAQ:DVAX)

HighTower Advisors LLC trimmed its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 2.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 38,222 shares of the biopharmaceutical company’s stock after selling 796 shares during the period. HighTower Advisors LLC’s holdings in Dynavax Technologies were worth $488,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Smartleaf Asset Management LLC increased its holdings in Dynavax Technologies by 463.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 2,034 shares in the last quarter. GAMMA Investing LLC lifted its position in Dynavax Technologies by 55.1% during the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 1,457 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in Dynavax Technologies in the fourth quarter worth approximately $71,000. Nisa Investment Advisors LLC raised its stake in Dynavax Technologies by 19.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 1,076 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of Dynavax Technologies during the 3rd quarter valued at $89,000. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Price Performance

Dynavax Technologies stock opened at $13.68 on Monday. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $14.63. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The firm’s fifty day moving average is $13.35 and its 200 day moving average is $12.51. The company has a market cap of $1.70 billion, a price-to-earnings ratio of 76.00 and a beta of 1.23.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.05. The business had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. Sell-side analysts forecast that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on DVAX. HC Wainwright reiterated a “buy” rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday, February 21st. StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, The Goldman Sachs Group cut Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.